Loading...

Sima Porten, MD, MPH

Title(s)Assistant Professor, Urology
SchoolSchool of Medicine
Phone415-885-3695
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sadighian M, Porten S. Gender differences in oncologic and functional outcomes in patients with bladder cancer undergoing radical cystectomy with urinary diversion. Curr Opin Urol. 2019 Jul 15. PMID: 31313715.
      View in: PubMed
    2. Porten SP, Master VA. Optimizing cystectomy outcomes. Cancer. 2019 Jul 12. PMID: 31299088.
      View in: PubMed
    3. Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019 May 16. PMID: 31103391.
      View in: PubMed
    4. Washington SL, Neuhaus J, Meng MV, Porten SP. Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer. Cancer Epidemiol Biomarkers Prev. 2019 May 15. PMID: 31092404.
      View in: PubMed
    5. Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019 May 12. PMID: 31092337.
      View in: PubMed
    6. Washington SL, Porten SP, Quanstrom K, Jin C, Bridge M, Finlayson E, Walter LC, Suskind AM. The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice. Urology. 2019 May; 127:19-23. PMID: 30822479.
      View in: PubMed
    7. Balakrishnan AS, Washington SL, Meng MV, Porten SP. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. Clin Genitourin Cancer. 2019 Jan 19. PMID: 30799130.
      View in: PubMed
    8. Porten SP. Epigenetic Alterations in Bladder Cancer. Curr Urol Rep. 2018 Oct 24; 19(12):102. PMID: 30357502.
      View in: PubMed
    9. Psutka SP, Porten S. Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape. Eur Urol Focus. 2018 09; 4(5):731-732. PMID: 30154044.
      View in: PubMed
    10. Porten SP, Gaither TW, Greene KL, Baradaran N, Anger JT, Breyer BN. Do Women Work Less Than Men in Urology: Data From the American Urological Association Census. Urology. 2018 Aug; 118:71-75. PMID: 29723591.
      View in: PubMed
    11. Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin Epigenetics. 2018; 10:19. PMID: 29456764.
      View in: PubMed
    12. Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP. Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PLoS One. 2017; 12(11):e0187975. PMID: 29140994.
      View in: PubMed
    13. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582. PMID: 28881475.
      View in: PubMed
    14. Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222. PMID: 27494900.
      View in: PubMed
    15. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724. PMID: 28753837.
      View in: PubMed
    16. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):78-86. PMID: 27511849.
      View in: PubMed
    17. Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015 Oct-Dec; 31(4):297-303. PMID: 26604440; PMCID: PMC4626913.
    18. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62. PMID: 26343003.
      View in: PubMed
    19. Sanford T, Porten S, Meng MV. Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison. PLoS One. 2015; 10(8):e0137141. PMID: 26317352; PMCID: PMC4552875.
    20. Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes. J Urol. 2015 Jul; 194(1):85-90. PMID: 25623742.
      View in: PubMed
    21. Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):517-23. PMID: 24921905.
      View in: PubMed
    22. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51. PMID: 24819235; PMCID: PMC4266691.
    23. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. PMID: 24633966; PMCID: PMC4440575.
    24. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65. PMID: 24525232; PMCID: PMC4011497.
    25. Zaid UB, Porten SP, Cinman NM, Sanford TH, Breyer BN. Xanthogranulomatous pyelonephritis presenting with a left flank mass. Case Rep Med. 2013; 2013:362194. PMID: 24367381.
      View in: PubMed
    26. Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol. 2014 Feb; 65(2):267-9. PMID: 24199712; PMCID: PMC4676267.
    27. Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol. 2013 Sep; 23(5):435-43. PMID: 23880739.
      View in: PubMed
    28. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7. PMID: 23911605.
      View in: PubMed
    29. Cinman NM, McAninch JW, Porten SP, Myers JB, Blaschko SD, Bagga HS, Breyer BN. Gunshot wounds to the lower urinary tract: a single-institution experience. J Trauma Acute Care Surg. 2013 Mar; 74(3):725-30; discussion 730-1. PMID: 23425728; PMCID: PMC4122300.
    30. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):183-7. PMID: 23411385.
      View in: PubMed
    31. Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR. Active surveillance: does serial prostate biopsy increase histological inflammation? Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):165-9. PMID: 23318528.
      View in: PubMed
    32. Porten SP, Cooperberg MR. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012 Sep; 22(5):385-9. PMID: 22842681.
      View in: PubMed
    33. Garcia M, Porten S, Lue TF. Commentary on refractory ischemic priapism. Transl Androl Urol. 2012 Mar; 1(1):61-5. PMID: 26813294; PMCID: PMC4713211.
    34. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol. 2011 Nov; 186(5):1825-9. PMID: 21944082.
      View in: PubMed
    35. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800. PMID: 21632511.
      View in: PubMed
    36. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7. PMID: 21478037.
      View in: PubMed
    37. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60. PMID: 21419438.
      View in: PubMed
    38. Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71. PMID: 21347810; PMCID: PMC3099175.
    39. Whitson JM, Porten SP, Carroll PR. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. Nat Rev Urol. 2011 Mar; 8(3):124-5. PMID: 21304508.
      View in: PubMed
    40. Myers JB, Porten SP, McAninch JW. The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate and urethral blood supply. Urology. 2011 May; 77(5):1223-7. PMID: 21215434.
      View in: PubMed
    41. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34. PMID: 21115873; PMCID: PMC3058278.
    42. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6. PMID: 20846693.
      View in: PubMed
    43. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010 Jun; 183(6):2244-8. PMID: 20400141.
      View in: PubMed
    44. Eisner BH, Porten SP, Bechis SK, Stoller ML. The role of race in determining 24-hour urine composition in white and Asian/Pacific Islander stone formers. J Urol. 2010 Apr; 183(4):1407-11. PMID: 20171692.
      View in: PubMed
    45. Eisner BH, Porten SP, Bechis SK, Stoller ML. Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis. J Urol. 2010 Feb; 183(2):576-9. PMID: 20018328.
      View in: PubMed
    46. Wallner LP, Porten S, Meenan RT, O'Keefe Rosetti MC, Calhoun EA, Sarma AV, Clemens JQ. Prevalence and severity of undiagnosed urinary incontinence in women. Am J Med. 2009 Nov; 122(11):1037-42. PMID: 19854332; PMCID: PMC2768650.
    47. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5. PMID: 19681901; PMCID: PMC2821458.
    48. Porten S, Kielb S. Diagnosis of female diverticula using magnetic resonance imaging. Adv Urol. 2008; 213516. PMID: 18604291; PMCID: PMC2441842.
    49. Diaz Saldano D, Chaviano AH, Maizels M, Yerkes EB, Cheng EY, Losavio J, Porten SP, Sullivan C, Zebold KF, Hagerty J, Kaplan WE. Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes. J Urol. 2007 Oct; 178(4 Pt 2):1758-61; discussion 1762. PMID: 17707433.
      View in: PubMed
    50. Le TT, Wroblewski E, Patel S, Riesenberg AN, Brown NL. Math5 is required for both early retinal neuron differentiation and cell cycle progression. Dev Biol. 2006 Jul 15; 295(2):764-78. PMID: 16690048.
      View in: PubMed
    51. Brown NL, Patel S, Brzezinski J, Glaser T. Math5 is required for retinal ganglion cell and optic nerve formation. Development. 2001 Jul; 128(13):2497-508. PMID: 11493566; PMCID: PMC1480839.